Expertise in
46
conditions

Dr. Brian A. Dicarlo

Oncology
CommonSpirit Health
UCLA Health Hematology Oncology
892 Aerovista Pl, Ste 240, 
San Luis Obispo, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Expertise in
46
conditions
CommonSpirit Health
UCLA Health Hematology Oncology
892 Aerovista Pl, Ste 240, 
San Luis Obispo, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Dicarlo is an Oncologist in San Luis Obispo, California. Dr. Dicarlo is highly rated in 46 conditions, according to our data. His top areas of expertise are Familial Pancreatic Cancer, Paget Disease of the Breast, Lung Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. Dicarlo is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
State University Of New York At Brooklyn(Medical)
Specialties
Oncology
Licenses
Internal Medicine in CA
Board Certifications
Internal Medicine (Sub: Hematology)
Internal Medicine (Sub: Medical Oncology)
Fellowships
New York Presbyterian Hospital - Weill Cornell
Hospital Affiliations
Marian Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UCLA Health Hematology Oncology
892 Aerovista Pl, Ste 240, San Luis Obispo, CA 93401
Call: 805-541-8252

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

6 Total Publications

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Journal: Breast cancer research : BCR
Published: January 05, 2023
View All 6 Publications
Similar Doctors
Thomas J. Spillane
Expertise in
74
conditions
Dr. Thomas J. Spillane
Oncology
Expertise in
74
conditions
Dr. Thomas J. Spillane
Oncology

Cancer Center - Dignity Health - San Luis Obispo, CA

715 Tank Farm Rd, Suite C, 
San Luis Obispo, CA 
 (0.3 miles away)
805-543-5577
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Tom Spillane believes in an integrative approach to the management of his patients. His definition of an integrative approach combines the best of the updated western medicine technology, complementary care, clinical trials and local psychosocial support services.Dr. Spillane co-founded the Hearst Cancer Resource Center in 2008, as well as the Surfing for Hope Foundation  in 2011, a program that among other services takes cancer survivors and children whose parents are battling cancer, on monthly surf sessions.Board Certification:Oncology, HematologyMedical School:University of California, DavisMedical Oncology Residency:University of California, IrvineFellowship Training:University of California, IrvineAreas of Interest:Brain tumors, Breast Cancer, GI Cancers, Head and Neck Cancer, Lung Cancer, Melanoma. Dr. Spillane is highly rated in 74 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Lynch Syndrome.

Expertise in
16
conditions
Dr. Gregory M. Heestand
Oncology | Hematology Oncology | Hematology
Expertise in
16
conditions
Dr. Gregory M. Heestand
Oncology | Hematology Oncology | Hematology

Stanford Health Care

1310 Las Tablas Rd, Suite 204, 
Templeton, CA 
 (22.0 miles away)
805-434-3458
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregory Heestand is an Oncologist and a Hematologist Oncology provider in Templeton, California. Dr. Heestand is highly rated in 16 conditions, according to our data. His top areas of expertise are Fibrolamellar Carcinoma, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Tissue Biopsy.

Lin Soe
Expertise in
52
conditions
Dr. Lin Soe
Oncology | Internal Medicine
Expertise in
52
conditions
Dr. Lin Soe
Oncology | Internal Medicine

Cancer Center - Dignity Health - San Luis Obispo, CA

715 Tank Farm Rd, Suite C, 
San Luis Obispo, CA 
 (0.3 miles away)
805-543-5577
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Board Certification:Oncology & HematologyFellowship Training:Oncology & Hematology from University California DavisInternal Medicine Residency:Cornell UniversityMedical School:Institute of Medicine I, Ragoon, BurmaEducation:Masters of Public Health and Tropical Medicine Tulane UniversityAreas of Interest: Benign Hematology, Breast Cancer, Gastrointestinal Malignancies, Lung Cancer, Solid Tumors. Dr. Soe is highly rated in 52 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma.

VIEW MORE Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dicarlo's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Dicarlo is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Familial Prostate Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    View All 19 Distinguished Conditions
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Dicarlo is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Dicarlo is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Ampullary Cancer
      Dr. Dicarlo is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Breast Cancer in Men
      Dr. Dicarlo is
      Advanced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Dicarlo is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Dicarlo is
      Advanced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    View All 27 Advanced Conditions
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Acute Myelomonocytic Leukemia
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Adrenal Cancer
      Dr. Dicarlo is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adult Immune Thrombocytopenia
      Dr. Dicarlo is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    View All 114 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    1. Homepage
    2. Oncologists San Luis Obispo, CA
    3. Dr. Brian A. Dicarlo
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.